欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Cinryze
适用类别Human
治疗领域Angioedemas, Hereditary
通用名/非专利名称C1 inhibitor (human)
活性成分C1 inhibitor (human)
产品号EMEA/H/C/001207
患者安全信息No
许可状态Authorised
ATC编码B06AC01
是否额外监管Yes
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2011/06/15
上市许可开发者/申请人/持有人Takeda Manufacturing Austria AG
人用药物治疗学分组c1-inhibitor, plasma derived;Drugs used in hereditary angioedema
兽用药物治疗学分组
审评意见日期2011/03/17
欧盟委员会决定日期2025/05/08
修订号25
治疗适应症Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
适用物种
兽用药物ATC编码
首次发布日期2018/03/20
最后更新日期2025/06/18
产品说明书https://www.ema.europa.eu/en/documents/product-information/cinryze-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase